Has Terry Styles, MD received payments from drug or device companies?

Yes. Drug and device makers reported $642 in general payments to Terry Styles, MD across 9 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Terry Styles, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Terry Styles, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Terry Styles, MD

Radiation Oncology · Tulsa, OKNPI 1073545380

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $570 of the $642 with a category attached, or 88.8%. 5 manufacturers reported payments, led by AstraZeneca at 36.1% of the total. Reporting peaked in 2022 at $316 and has fallen 92.4% since, to $24 in 2023. That places this record below the midpoint for radiation oncology clinicians in OK, where the typical reported total is $823.

$642in general payments, 2019–2025

Across 9 payments — averaging $71.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$232
Myovant Sciences Inc.$136
Covidien LP$128
Boston Scientific$122
Sumitomo Pharma America, Inc.$24

What the payments were for

Food & beverage$57089%
Education$7211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	2	$232
Myovant Sciences Inc.	3	$136
Covidien LP	1	$128
Boston Scientific	2	$122
Sumitomo Pharma America, Inc.	1	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$642 in reported general payments places this provider in the 45th percentile of 43 radiation oncology providers in Oklahoma.

See all radiation oncology providers in Oklahoma →

Medicare billing

Part B allowed, 2024

$194,322

Medicare patients

280

Services billed

2,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Tulsa

Diane HeatonTulsa$36K
Mykhanh NguyenTulsa$15K
Nathan UyTulsa$5K
Charles StewartTulsa$3K
Frederick WillisonTulsa$414
Stephen SackTulsa$373
Ralph JensenTulsa$67
William GoadTulsa$48
Jerry JaboinOklahoma City$14K
Walter WattsMuskogee$10K

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →